Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual Inflammasome Inhibitor K8
Inflammasome Therapeutics, a private, science-based company developing therapies for prevalent, degenerative diseases and sustained-release drug delivery systems, announced it has been awarded a second grant from the Bill & Melinda Gates Foundation. The new $1.3 million grant will be used to develop a 12-month bioerodible implant for women to provide prevention from HIV infection coupled with birth control. According to a Kaiser Family Foundation report released in March 2021, women represent more than half (55%) of all adults (15-49) living with HIV worldwide, and HIV (along with complications related to pregnancy) is the leading cause of death among women of reproductive age.